Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?

Stephen F. Andrews, Eric M. Horwitz, Steven J. Feigenberg, Debra F. Eisenberg, Alexandra L. Hanlon, Robert G. Uzzo, Alan Pollack

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND. Physicians involved in the care of men diagnosed with prostate carcinoma must assess the urgency of treatment. For those men who choose external beam radiation therapy (EBRT), the delay from the time of biopsy to treatment may be stressful. There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes. METHODS. The authors of the current study analyzed 1322 patients who were treated with EBRT alone. Overall survival (OS), cause specific survival (CSS), distant metastasis (DM), and freedom from biochemical failure (FFBF) were calculated. TTT was first analyzed at 4 intervals: < 3, 3-6, 6-9 and > 9 months, and at the median TTT. Cox multivariate analysis (MVA) was then performed with 2002 American Joint Commission on Cancer T-stage, Gleason score, prostate specific antigen (PSA), radiation dose, and TTT as covariates. RESULTS. There were no statistical differences in OS, CSS, DM, or FFBF among men whose EBRT began < 3, 3-6, 6-9, or > 9 months after diagnosis. This was also true at the median TTT of 3.1 months. A subgroup analysis was performed in which patients were stratified into low-, intermediate- and high-risk groups based on pretreatment PSA, Gleason score and AJCC T-stage. FFBF, and DM were calculated above and below the median TTT of 3.1 months. In this analysis, there was no statistically significant difference in FFBF or DM within the risk groups. CONCLUSIONS. Within the limits of the current study, data indicate that a treatment delay, even in high-risk patients, has little effect on clinical or biochemical outcome.

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalCancer
Volume104
Issue number2
DOIs
StatePublished - Jul 15 2005
Externally publishedYes

Fingerprint

Prostate
Radiotherapy
Carcinoma
Neoplasm Metastasis
Therapeutics
Survival
Neoplasm Grading
Prostate-Specific Antigen
Radiation
Multivariate Analysis
Joints
Physicians
Biopsy
Neoplasms

Keywords

  • Prostate carcinoma
  • Radiation therapy
  • Treatment delay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Andrews, S. F., Horwitz, E. M., Feigenberg, S. J., Eisenberg, D. F., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2005). Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer, 104(2), 299-304. https://doi.org/10.1002/cncr.21184

Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? / Andrews, Stephen F.; Horwitz, Eric M.; Feigenberg, Steven J.; Eisenberg, Debra F.; Hanlon, Alexandra L.; Uzzo, Robert G.; Pollack, Alan.

In: Cancer, Vol. 104, No. 2, 15.07.2005, p. 299-304.

Research output: Contribution to journalArticle

Andrews, SF, Horwitz, EM, Feigenberg, SJ, Eisenberg, DF, Hanlon, AL, Uzzo, RG & Pollack, A 2005, 'Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?', Cancer, vol. 104, no. 2, pp. 299-304. https://doi.org/10.1002/cncr.21184
Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG et al. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer. 2005 Jul 15;104(2):299-304. https://doi.org/10.1002/cncr.21184
Andrews, Stephen F. ; Horwitz, Eric M. ; Feigenberg, Steven J. ; Eisenberg, Debra F. ; Hanlon, Alexandra L. ; Uzzo, Robert G. ; Pollack, Alan. / Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?. In: Cancer. 2005 ; Vol. 104, No. 2. pp. 299-304.
@article{930c4730258b448189854f3363044e72,
title = "Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?",
abstract = "BACKGROUND. Physicians involved in the care of men diagnosed with prostate carcinoma must assess the urgency of treatment. For those men who choose external beam radiation therapy (EBRT), the delay from the time of biopsy to treatment may be stressful. There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes. METHODS. The authors of the current study analyzed 1322 patients who were treated with EBRT alone. Overall survival (OS), cause specific survival (CSS), distant metastasis (DM), and freedom from biochemical failure (FFBF) were calculated. TTT was first analyzed at 4 intervals: < 3, 3-6, 6-9 and > 9 months, and at the median TTT. Cox multivariate analysis (MVA) was then performed with 2002 American Joint Commission on Cancer T-stage, Gleason score, prostate specific antigen (PSA), radiation dose, and TTT as covariates. RESULTS. There were no statistical differences in OS, CSS, DM, or FFBF among men whose EBRT began < 3, 3-6, 6-9, or > 9 months after diagnosis. This was also true at the median TTT of 3.1 months. A subgroup analysis was performed in which patients were stratified into low-, intermediate- and high-risk groups based on pretreatment PSA, Gleason score and AJCC T-stage. FFBF, and DM were calculated above and below the median TTT of 3.1 months. In this analysis, there was no statistically significant difference in FFBF or DM within the risk groups. CONCLUSIONS. Within the limits of the current study, data indicate that a treatment delay, even in high-risk patients, has little effect on clinical or biochemical outcome.",
keywords = "Prostate carcinoma, Radiation therapy, Treatment delay",
author = "Andrews, {Stephen F.} and Horwitz, {Eric M.} and Feigenberg, {Steven J.} and Eisenberg, {Debra F.} and Hanlon, {Alexandra L.} and Uzzo, {Robert G.} and Alan Pollack",
year = "2005",
month = "7",
day = "15",
doi = "10.1002/cncr.21184",
language = "English",
volume = "104",
pages = "299--304",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?

AU - Andrews, Stephen F.

AU - Horwitz, Eric M.

AU - Feigenberg, Steven J.

AU - Eisenberg, Debra F.

AU - Hanlon, Alexandra L.

AU - Uzzo, Robert G.

AU - Pollack, Alan

PY - 2005/7/15

Y1 - 2005/7/15

N2 - BACKGROUND. Physicians involved in the care of men diagnosed with prostate carcinoma must assess the urgency of treatment. For those men who choose external beam radiation therapy (EBRT), the delay from the time of biopsy to treatment may be stressful. There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes. METHODS. The authors of the current study analyzed 1322 patients who were treated with EBRT alone. Overall survival (OS), cause specific survival (CSS), distant metastasis (DM), and freedom from biochemical failure (FFBF) were calculated. TTT was first analyzed at 4 intervals: < 3, 3-6, 6-9 and > 9 months, and at the median TTT. Cox multivariate analysis (MVA) was then performed with 2002 American Joint Commission on Cancer T-stage, Gleason score, prostate specific antigen (PSA), radiation dose, and TTT as covariates. RESULTS. There were no statistical differences in OS, CSS, DM, or FFBF among men whose EBRT began < 3, 3-6, 6-9, or > 9 months after diagnosis. This was also true at the median TTT of 3.1 months. A subgroup analysis was performed in which patients were stratified into low-, intermediate- and high-risk groups based on pretreatment PSA, Gleason score and AJCC T-stage. FFBF, and DM were calculated above and below the median TTT of 3.1 months. In this analysis, there was no statistically significant difference in FFBF or DM within the risk groups. CONCLUSIONS. Within the limits of the current study, data indicate that a treatment delay, even in high-risk patients, has little effect on clinical or biochemical outcome.

AB - BACKGROUND. Physicians involved in the care of men diagnosed with prostate carcinoma must assess the urgency of treatment. For those men who choose external beam radiation therapy (EBRT), the delay from the time of biopsy to treatment may be stressful. There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes. METHODS. The authors of the current study analyzed 1322 patients who were treated with EBRT alone. Overall survival (OS), cause specific survival (CSS), distant metastasis (DM), and freedom from biochemical failure (FFBF) were calculated. TTT was first analyzed at 4 intervals: < 3, 3-6, 6-9 and > 9 months, and at the median TTT. Cox multivariate analysis (MVA) was then performed with 2002 American Joint Commission on Cancer T-stage, Gleason score, prostate specific antigen (PSA), radiation dose, and TTT as covariates. RESULTS. There were no statistical differences in OS, CSS, DM, or FFBF among men whose EBRT began < 3, 3-6, 6-9, or > 9 months after diagnosis. This was also true at the median TTT of 3.1 months. A subgroup analysis was performed in which patients were stratified into low-, intermediate- and high-risk groups based on pretreatment PSA, Gleason score and AJCC T-stage. FFBF, and DM were calculated above and below the median TTT of 3.1 months. In this analysis, there was no statistically significant difference in FFBF or DM within the risk groups. CONCLUSIONS. Within the limits of the current study, data indicate that a treatment delay, even in high-risk patients, has little effect on clinical or biochemical outcome.

KW - Prostate carcinoma

KW - Radiation therapy

KW - Treatment delay

UR - http://www.scopus.com/inward/record.url?scp=22244443793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244443793&partnerID=8YFLogxK

U2 - 10.1002/cncr.21184

DO - 10.1002/cncr.21184

M3 - Article

C2 - 15954083

AN - SCOPUS:22244443793

VL - 104

SP - 299

EP - 304

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -